SEARCH

SEARCH BY CITATION

References

  • Alexi T. and Hefti F. (1993) Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture. Neuroscience 55, 903918.DOI: 10.1016/0306-4522(93)90307-2
  • Beck K. D., Knusel B. and Hefti F. (1993) The nature of the trophic action of brain-derived neurotrophic factor, des (1–3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 52, 855866.
  • Beck K. D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R. A., Rosenthal A. and Hefti F. (1995) Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373, 339341.
  • Blum M. (1998) A null mutation in TGF-α leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat. Neurosci. 1, 374377.
  • Canesi L., Malatesta M., Battistelli S., Ciacci C., Gallo G. and Gazzanelli G. (2000) Immunoelectron microscope analysis of epidermal growth factor receptor (EGFR) in isolated Mytilus galloprovincialis (Lam.) digestive gland cells: evidence for ligand-induced changes in EGFR intracellular distribution. J. Exp. Zool. 286, 690698.
  • Casper D., Mytilineou C. and Blum M. (1991) EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. J. Neurosci. Res. 30, 372381.
  • Casper D., Roboz G. J. and Blum M. (1994) Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture. J. Neurochem. 62, 21662177.
  • Cirulli F. and Alleva E. (1994) Effects of repeated administrations of EGF and TGF-alpha on mouse neurobehavioral development. Neurotoxicology 15, 819825.
  • Date I., Yoshimoto Y., Imaoka T., Miyoshi Y., Gohda Y., Furuta T., Asari S. and Ohmoto T. (1993) Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging. Brain Res. 621, 150154.DOI: 10.1016/0006-8993(93)90312-B
  • Dluzen D. E., Story G. M., Xu K., Kucera J. and Walro J. M. (1999) Alterations in nigrostriatal dopaminergic function within BDNF mutant mice. Exp. Neurol. 160, 500507.DOI: 10.1006/exnr.1999.7225
  • Earp H. S., Dawson T. L., Li X. and Yu H. (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35, 115132.DOI: 10.1007/BF00694752
  • Fawcett J. W., Barker R. A. and Dunnett S. B. (1995) Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp. Brain Res. 106, 275282.
  • Ferrari G., Toffano G. and Skaper S. D. (1991) Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor. J. Neurosci. Res. 30, 493497.DOI: 10.1002/jnr.490300306
  • Frim D. M., Uhler T. A., Galpern W. R., Beal M. F., Breakefield X. O. and Isacson O. (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent l-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl Acad. Sci. USA 91, 51045108.
  • Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., Someya T., Kakita A., Takahashi H. and Nawa H. (2002) Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol. Psychiatry 7, 673682.DOI: 10.1038/sj.mp.4001081
  • Futamura T., Kakita A., Tohmi M., Sotoyama H., Takahashi H. and Nawa H. (2003) Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol. Psychiatry 8, 1929.DOI: 10.1038/sj.mp.4001138
  • Gill S. S., Patel N. K., Hotton G. R., O'Sullivan K., McCarter R., Bunnage M., Brooks D. J., Svendsen C. N. and Heywood P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat. Med. 9, 589595.DOI: 10.1038/nm850
  • Ginanneschi A., Degl'Innocenti F., Magnolfi S., Maurello M. T., Catarzi L., Marini P. and Amaducci L. (1988) Evaluation of Parkinson's disease: reliability of three rating scales. Neuroepidemiology 7, 3841.
  • Gomez-Pinilla F., Knauer D. J. and Nieto-Sampedro M. (1988) Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain Res. 438, 385390.DOI: 10.1016/0006-8993(88)91369-8
  • Hadjiconstantinou M., Fitkin J. G., Dalia A. and Neff N. H. (1991) Epidermal growth factor enhances striatal dopaminergic parameters in the l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 57, 479482.
  • Hanke M., Farkas L. M., Jakob M., Ries R., Pohl J. and Sullivan A. M. (2004) Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurons in vitro and in vivo. Neuroscience 124, 757766.DOI: 10.1016/j.neuroscience.2003.12.033
  • Hilakivi-Clarke L. A. and Goldberg R. (1993) Effects of tryptophan and serotonin uptake inhibitors on behavior in male transgenic transforming growth factor α mice. Eur. J. Pharmacol. 237, 101108.DOI: 10.1016/0014-2999(93)90098-3
  • Ho A. and Blum M. (1997) Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1β in the striatum of young and middle-aged mice. Exp. Neurol. 148, 348359.DOI: 10.1006/exnr.1997.6659
  • Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D., Squinto S. P. and Lindsay R. M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230232.DOI: 10.1038/350230a0
  • Ishiyama J., Saito H. and Abe K. (1991) Epidermal growth factor and basic fibroblast growth factor promote the generation of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci. Res. 12, 403411.DOI: 10.1016/0168-0102(91)90071-6
  • Iwakura Y., Nagano T., Kawamura M., Horikawa H., Ibaraki K., Takei N. and Nawa H. (2001) N-methyl-d-aspartate-induced α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor down-regulation involves interaction of the carboxyl terminus of GluR2/3 with Pick1. Ligand-binding studies using Sindbis vectors carrying AMPA receptor decoys. J. Biol. Chem. 276, 40 02540 032.
  • Iwakura Y., Shishido Y. and Nawa H. (2002) Regulated release of EGF, TGFα and HB-EGF from striatal neurons; their trophic activity on midbrain dopaminergic neurons. Soc. Neurosci. Abstr. 32, 427.11.
  • Jellinger K. A. (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153197.
  • Jones K. R., Farinas I., Backus C. and Reichardt L. F. (1994) Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 76, 989999.
  • Kholodilov N., Yarygina O., Oo T. F., Zhang H., Sulzer D., Dauer W. and Burke R. E. (2004) Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. J. Neurosci. 24, 31363146.
  • Lin L. F., Doherty D. H., Lile J. D., Bektesh S. and Collins F. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 11301132.
  • Mandel S., Grunblatt E. and Youdim M. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural. Transm. Suppl. 60, 117124.
  • Mayeux R. (2003) Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81104.
  • Misumi Y. and Kawano H. (1998) The expressions of epidermal growth factor receptor mRNA and protein gene product 9.5 in developing rat brain. Dev. Brain Res. 107, 19.
  • Mogi M., Togari A., Kondo T., Mizuno Y., Kogure O., Kuno S., Ichinose H. and Nagatsu T. (2001) Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci. Lett. 300, 179181.
  • Moore M. W., Klein R. D., Farinas I. et al. (1996) Renal and neuronal abnormalities in mice lacking GDNF. Nature 382, 7679.
  • Morrison R. S., Kornblum H. I., Leslie F. M. and Bradshaw R. A. (1987) Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor. Science 238, 7275.
  • Nawa H. and Takei N. (2001) BDNF as an anterophin; a novel neurotrophic relationship between brain neurons. Trends Neurosci. 24, 683684.
  • Nawa H., Carnahan J. and Gall C. (1995) BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. Eur. J. Neurosci. 7, 15271535.
  • Nieuwenhuys R., Voogd J. and Van Huijzen Chr (1988) The Human Central Nervous System: a Synopsis and Atlas. Springer-Verlag, Berlin.
  • Olson L. (1997) The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Trends Neurosci. 20, 277279.
  • Poo M. M. (2001) Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2, 2432.
  • Reynolds B. A., Tetzlaff W. and Weiss S. (1992) A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 12, 45654574.
  • Rosenblad C., Martinez-Serrano A. and Bjorklund A. (1998) Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82, 129137.
  • Seroogy K. B., Numan S., Gall C. M., Lee D. C. and Kornblum H. I. (1994) Expression of EGF receptor mRNA in rat nigrostriatal system. Neuroreport 6, 105108.
  • Sibilia M., Steinbach J. P., Stingl L., Aguzzi A. and Wagner E. F. (1998) A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17, 719731.
  • Sokolov B. P. (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of ‘neuroleptic-free’ schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 71, 24542464.
  • Takei N., Skoglosa Y. and Lindholm D. (1998) Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. J. Neurosci. Res. 54, 698706.
  • Tseng J. L., Baetge E. E., Zurn A. D. and Aebischer P. (1997) GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17, 325333.
  • Ullrich A. and Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61, 202212.
  • Ullrich A., Coussens L., Hayflick J. S. et al. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418425.
  • Unsicker K. (1994) Growth factors in Parkinson's disease. Prog. Growth Factor Res. 5, 7387.
  • Ventrella L. L. (1993) Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway. J. Neurosurg. Sci. 37, 18.
  • Volpe B. T., Wildmann J. and Altar C. A. (1998) Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 83, 741748.
  • Walker R. A. (1998) The erbB/HER type 1 tyrosine kinase receptor family. J. Pathol. 185, 234235.
  • Warner T. T. and Schapira A. H. (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53, S16S23.
  • Werner M. H., Nanney L. B., Stoscheck C. M. and King L. E. (1988) Localization of immunoreactive epidermal growth factor receptors in human nervous system. J. Histochem. Cytochem. 36, 8186.
  • Xian C. J. and Zhou X. F. (2000) Roles of transforming growth factor-alpha and related molecules in the nervous system. Mol. Neurobiol. 20, 157183.
  • Yasuhara T., Shingo T., Kobayashi K., Takeuchi A., Yano A., Muraoka K., Matsui T., Miyoshi Y., Hamada H. and Date I. (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur. J. Neurosci. 19, 14941504.